Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) — Market Cap & Net Worth
Market Cap & Net Worth: Galmed Pharmaceuticals Ltd (GLMD)
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) has a market capitalization of $3.77 Million ($3.77 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28869 globally and #5668 in its home market, demonstrating a -7.15% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Galmed Pharmaceuticals Ltd's stock price $0.57 by its total outstanding shares 6599654 (6.60 Million). Analyse GLMD cash flow conversion to see how efficiently the company converts income to cash.
Galmed Pharmaceuticals Ltd Market Cap History: 2015 to 2026
Galmed Pharmaceuticals Ltd's market capitalization history from 2015 to 2026. Data shows change from $9.04 Billion to $3.77 Million (-53.36% CAGR).
Index Memberships
Galmed Pharmaceuticals Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #858 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2745 of 3165 |
Weight: Galmed Pharmaceuticals Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Galmed Pharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Galmed Pharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3981.16x
Galmed Pharmaceuticals Ltd's market cap is 3981.16 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.17 Billion | $467.00K | -$16.95 Million | 8928.61x | N/A |
| 2017 | $10.87 Billion | $1.08 Million | -$12.30 Million | 10018.09x | N/A |
| 2018 | $8.11 Billion | $2.04 Million | -$9.86 Million | 3981.16x | N/A |
Competitor Companies of GLMD by Market Capitalization
Companies near Galmed Pharmaceuticals Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Galmed Pharmaceuticals Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Galmed Pharmaceuticals Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Galmed Pharmaceuticals Ltd's market cap moved from $9.04 Billion to $ 3.77 Million, with a yearly change of -53.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.77 Million | -23.92% |
| 2025 | $4.95 Million | -76.47% |
| 2024 | $21.05 Million | -41.58% |
| 2023 | $36.03 Million | -93.93% |
| 2022 | $593.97 Million | -72.53% |
| 2021 | $2.16 Billion | -41.48% |
| 2020 | $3.69 Billion | -46.19% |
| 2019 | $6.87 Billion | -15.37% |
| 2018 | $8.11 Billion | -25.36% |
| 2017 | $10.87 Billion | +160.68% |
| 2016 | $4.17 Billion | -53.88% |
| 2015 | $9.04 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Galmed Pharmaceuticals Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.77 Million USD |
| MoneyControl | $3.77 Million USD |
| MarketWatch | $3.77 Million USD |
| marketcap.company | $3.77 Million USD |
| Reuters | $3.77 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes me… Read more